Adjuvant Chemotherapy with S-1 in Breast Cancer Patients after Primary Systemic ChemotherapyAkihiko Osaki*
Department of Breast Oncology, Saitama Medical University International Medical Center, Japan
- *Corresponding Author:
- Akihiko Osaki
Department of Breast Oncology
Saitama Medical University International Medical Center, Japan
Tel: 81 42 984 4670
E-mail: [email protected]
Received Date: January 05, 2016; Accepted Date: February 15, 2016; Published Date: February 19, 2016
Citation: Akihiko Osaki (2016) Adjuvant Chemotherapy with S-1 in Breast Cancer Patients after Primary Systemic Chemotherapy. Chemo Open Access 5:187. doi: 10.4172/2167-7700.1000187
Copyright: © 2016 Osaki A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,distribution, and reproduction in any medium, provided the original author and source are credited.
Additional therapy following definitive breast surgery after primary systemic chemotherapy (PSC) has not been correctly evaluated. Two unsolved problems regarding additional chemotherapy following PSC in advanced breast cancer are the subjects of this article. First is the prognostic impact of additional chemotherapy after surgery in patients with residual disease after completion of standard PSC, and second is the use of oral anticancer drugs such as S-1, which are known as metronomic chemotherapy, in this setting. Although there are many ongoing trials for breast cancer patients with residual disease after PSC in various subtypes, survival benefit has not been validated in clinical trials. Orally effective anticancer drugs such as S-1 and capecitabine can be further candidates for additional postoperative chemotherapy after PSC. Further studies are needed to evaluate the usefulness of these metronomic chemotherapies in this setting.